4-(aminomethyl) benzamides as novel anti-ebola agents
Ended Project Grant Awarded Last action
- Award ID
- R42AI126971
- Recipient
-
Chicago Biosolutions Inc. UEI KJL4YQ7KSEK9
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,881,299
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Funding
-
- $3,898,911.00 Federal
- $982,388.00 Non-federal
- Place of performance
- Illinois, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $982,388 | $0 | |
| Amendment | $982,388 | $982,388 | |
| Amendment | $961,660 | $0 | |
| Original award | $972,475 | $0 |
Quick answers
Who received award R42AI126971?
R42AI126971 was awarded to Chicago Biosolutions Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 7, 2016.
How much is award R42AI126971 worth?
$4,881,299 has been obligated on R42AI126971: $3,898,911 in federal funding and $982,388 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award